新科技经济理论创新探究

进入新世纪以来,新一轮科技变革推动下的经济增长正成为社会经济的主要推动力量,而科技创新发展与经济理论创新探索也呈现出新的态势与特征。对新技术经济理论进行创新性研究,需要用科学的分析范式对科技起源及科技进步演化的过程进行分析,并思考其对社会经济发展的影响作用。对马克思科技经济理论的梳理和思考有利于从原有理论体系中找到构建新科技经济创新理论的依据,结合新时期的新经济秩序形态,进行更深入的研究探索。而在新的科技经济时代背景下,社会经济发展与科技系统进步良性互动,两者协同统一的发展模式,以及其与现实社会经济生活的价值对接都是新科技创新理论探索的重要议题。     

国际汽车经济的技术发展概况——基于专利数据的分析

世界汽车产业的第四次技术变革,为以发展汽车产业等战略性产业为主的中国提高自主创新能力,转变经济增长方式和提高经济增长质量提供了重要契机。文章主要对世界汽车产业的技术专利情况进行了分析研究,以了解当前世界汽车专利技术的发展概况,发现中国汽车产业的当前的发展差距和机会。     

知识经济时代呼唤工程咨询监理业

如何面对知识经济的挑战,如何迎接知识经济的到来?对于以知识和智力劳动来创造价值的,与知识经济有着天然亲情的咨询机构,在思考和解答这个问题时,应该是一个先知先觉者.应透过当前我国国有大中型企业不景气,咨询市场难开拓的暂时现象,看到咨询业大有作为的明天.本文仅对咨询业的一个新兴领域--"信息工程咨询监理业"进行剖析,试图对以上问题作出几点回答.     

对我国生态环境保护的初步探讨

中国是世界上最大的发展中国家,由于现代工农业生产而造成了严重的环境污染,尤其是大量使用农用化学品所导致的生态失调与环境破坏,已严重威胁到人类生存环境及生活健康。今后社会发展必须大力提倡与推广无公害、无污染的清洁生产,全面实现生产的"零污染"与废物的"零排放"、保护环境与追求生态和谐的发展目标。     

Microfinance and gender inequality: cross-country evidence

Microfinance enables poor women to engage in income-generating activities, which helps them become financially independent, strengthening their decision-making power within the household and society. Consequently, microfinance has the potential to reduce gender inequality (GI). Case-study evidence from across the developing world both supports and contradicts this hypothesis. We therefore revisit this issue using macroeconomic cross-country panel data for 64 developing economies over the period 2003–2014. We find that women’s participation in microfinance is associated with a reduction in GI. However, regional interactions reveal that cultural factors are likely to influence the GI–microfinance nexus.     

Real-world comparison of all-cause hospitalizations,hospitalizations due to stroke and major bleeding,and costs for non-valvular atrial fibrillation patients prescribed oral anticoagulants in a US health plan

Aims: To compare the risk of all-cause hospitalization and hospitalizations due to stroke/systemic embolism (SE) and major bleeding, as well as associated healthcare costs for non-valvular atrial fibrillation (NVAF) patients initiating apixaban, dabigatran, rivaroxaban, or warfarin.

Materials and methods: NVAF patients initiating apixaban, dabigatran, rivaroxaban, or warfarin were selected from the OptumInsight Research Database from January 1, 2013–September 30, 2015. Propensity score matching (PSM) was performed between apixaban and each oral anticoagulant. Cox models were used to estimate the risk of stroke/SE and major bleeding. Generalized linear and 2-part models were used to compare healthcare costs.

Results: Of the 47,634 eligible patients, 8,328 warfarin-apixaban pairs, 3,557 dabigatran-apixaban pairs, and 8,440 rivaroxaban-apixaban pairs were matched. Compared to apixaban, warfarin patients were associated with a significantly higher risk of all-cause (hazard ratio [HR]?=?1.30; 95% confidence interval [CI]?=?1.21–1.40) as well as stroke/SE-related (HR?=?1.60; 95% CI?=?1.23–2.07) and major bleeding-related (HR?=?1.95; 95% CI?=?1.60–2.39) hospitalization; rivaroxaban patients were associated with a higher risk of all-cause (HR?=?1.15; 95% CI?=?1.07–1.24) and major bleeding-related hospitalization (HR?=?1.71; 95% CI?=?1.39–2.10); and dabigatran patients were associated with a higher risk of major bleeding hospitalization (HR?=?1.46, 95% CI?=?1.02–2.10). Warfarin patients had significantly higher major bleeding-related and total all-cause healthcare costs compared to apixaban patients. Rivaroxaban patients had significantly higher major bleeding-related costs compared to apixaban patients. No significant results were found for the remaining comparisons.

Limitations: No causal relationships can be concluded, and unobserved confounders may exist in this retrospective database analysis.

Conclusions: This study demonstrated a significantly higher risk of hospitalization (all-cause, stroke/SE, and major bleeding) associated with warfarin, a significantly higher risk of major bleeding hospitalization associated with dabigatran or rivaroxaban, and a significantly higher risk of all-cause hospitalization associated with rivaroxaban compared to apixaban. Lower major bleeding-related costs were observed for apixaban patients compared to warfarin and rivaroxaban patients.     

Economic evaluation of human urinary kallindinogenase for patients with acute ischemic stroke in China

Objectives: In China, both human urinary kallindinogenase (HUK) and 3-n-butylphthalide (NBP) are recommended for clinical use to improve cerebral blood circulation during an acute ischemic stroke (AIS). The objective was to evaluate the economic value of HUK vs NBP for patients with AIS from a Chinese payer’s perspective.

Methods: An economic evaluation based on data of patients who have been treated with either HUK (n?=?488) or NBP (n?=?885) from a prospective, phase IV, multi-center, clinical registry study (Chinese Acute Ischemic Stroke Treatment Outcome Registry, CASTOR) was conducted to analyze the cost and effectiveness of HUK vs NBP for AIS in China. Before the analysis, the patients were matched using propensity score. Both a cost-minimization analysis and a cost-effectiveness analysis were conducted to compare the matched pairs. A bootstrapping exercise was conducted for the matched arms to demonstrate the probability of one intervention being cost-effective over another for a given willingness-to-pay for an extra quality-adjusted life-year (QALY).

Results: After propensity score matching, 463 pairs were matched. The overall medical cost in the HUK arm is USD 2,701.20, while the NBP arm is USD 3,436.83, indicating HUK is preferred with cost-minimization analysis. Although the QALY gained in the HUK arm (0.77176) compared with the NBP arm (0.76831) is statistically insignificant (p?=?.4862), the cost-effectiveness analysis as exploratory analysis found that, compared with NBP, HUK is a cost-saving strategy with the lower costs of USD 735.63 and greater QALYs gained of 0.00345. Among the 5,000 bootstrapping replications, 100% indicates that HUK is cost-effective compared with NBP under a 1-time-GDP threshold; and 97.12% indicates the same under a 3-time-GDP threshold.

Conclusion: This economic evaluation study indicates that administrating HUK is a cost-saving therapy compared with NBP for managing blood flow during AIS in the Chinese setting.     

Entrepreneur’s creativity and firm-level innovation performance: bricolage as a mediator

Prior literature focuses on the direct influence of entrepreneur’s creativity on firm-level innovation performance, but it ignores the intermediate mechanism of how. This study examines the role of bricolage in mediating the relationship between entrepreneur’s creativity and innovation performance. We propose that in SMEs, entrepreneur’s creativity can facilitate bricolage, which in turn influences innovation performance. Furthermore, the extent to which entrepreneur’s creativity can influence bricolage depends on firm age. Survey data from 249 SMEs indicate that bricolage functions as a mediator in the relationship between entrepreneur’s creativity and innovation performance. Entrepreneur’s creativity has a stronger effect on bricolage for young firms than for old firms.     

Does default point vary with firm size?

This article aims to improve the predictive ability of KMV model by distinguishing firm size. The evidence suggests that default point would vary with firm size. Using the method of particle swarm optimization, we obtain the optimal default point separately for large firms and small firms. Several statistical tests such as the model confidence set methodology show that our relatively tractable model is more likely to have the strongest predictive ability.